external image 200px-GlaxoSmithKline_logo.svg.png

About GSK


GSK is a leading company in the healthcare industry, which is an interesting industry for our study because of the unique challenges such businesses will face. GSK is in a business that requires highly risky investments due to profound uncertainty and long time horizons for R&D. In an environment of rapid advances in drug science knowledge, scientists and engineers also need to learn fast to keep pace with the changes as well as integrate capabilities across a broad spectrum of scientific and technological knowledge bases in order to bring research ideas from the lab to the market.
When we hear about GSK in school, we think immediately about science. However, due to the complex challenges the business faces, science contributes only one part of the company’s success. In GSK, scientists and engineers are not only engaged in R&D, they must also learn how to ensure the smooth and rapid transition of their newly developed products into full-scale manufacture, and the consistent supply of high quality products across the world.

Video on GSK's involvement in London 2012 Olympics as official provider of laboratory services.






Market Capabilities

Pharmaceutical
GSK’s pharmaceuticals arm - the third-largest in the world in terms of revenue - develops and makes available medicines to treat a broad range of diseases including asthma, cancer, virus control, infections, mental health, diabetes, and digestive conditions.
Vaccines
GSK’s vaccines business is one of the largest in the world, producing paediatric and adult vaccines against a range of infectious diseases. In 2011, GSK distributed 1.1 billion doses to 173 countries, of which over 80% were supplied to developing countries.
Consumer Health Products
GSK develops and markets a range of consumer health products based on scientific innovation with leading positions in three categories:
  • Over-the-counter medicines including Gaviscon and Panadol
  • Oral healthcare such as Aquafresh and Sensodyne
  • Nutritional healthcare such as Lucozade, Ribena and Horlicks

external image ribena.jpgexternal image horlicks.jpgexternal image panadolrapidcaplets20.jpgexternal image sensodyne%5B1%5D.png



Corporate Responsibility

GSK’s Corporate Responsibility Principles are underpinned by our values and identify their key responsibility issues. They provide guidance for employees on the standards to which GSK is committed:

  1. Access to medicines
    • Improve access to medicines in middle-income and least developed countries
    • Research and develop medicines to treat diseases of the developing world

  2. Standards of ethical conduct
    • Embedding ethical values in the organization

  3. Research and Innovation
    • Policy on use of animals in research and development
    • Research integrity and transparency
    • R&D on treatments for rare conditions and for diseases of the developing world
    • Potential of stem cell science for regenerative medicines

  4. Products and customers
    • Disclosure of payments to healthcare professionals

  5. Caring for the environment
    • Environmental sustainability strategy
    • Management of environmental risks in manufacturing

Here's a video on GSK's development of malaria vaccine:






GSK in Singapore

GSK forged first-in-Asia partnerships with Singapore in sustainable manufacturing, pharmaceutical R&D and healthcare policy, as part of the GSK-Singapore 10-year Strategic Roadmap, to develop future solutions for the healthcare sector.

external image GSK-bldg-Singapore.jpg

Besides pharmaceutical and consumer healthcare operations, Singapore serves as the headquarters for GSK's Asia-Pacific operations and houses the Singapore Research Centre at Biopolis. In addition to a new vaccine plant opened in 2009, GSK has two global manufacturing and supply sites located in Singapore. In 2009, GSK’s investment in the city-state has exceeded S$1.5 billion



Related resources: